Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Active transforming growth factor-β2 in the aqueous humor of posterior polymorphous corneal dystrophy patients

A. Stadnikova, L. Dudakova, P. Skalicka, Z. Valenta, M. Filipec, K. Jirsova,

. 2017 ; 12 (4) : e0175509. [pub] 20170417

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023139

PURPOSE: Posterior polymorphous corneal dystrophy (PPCD) is characterized by abnormal proliferation of corneal endothelial cells. It was shown that TGF-β2 present in aqueous humor (AH) could help maintaining the corneal endothelium in a G1-phase-arrest state. We wanted to determine whether the levels of this protein are changed in AH of PPCD patients. METHODS: We determined the concentrations of active TGF-β2 in the AH of 29 PPCD patients (42 samples) and 40 cadaver controls (44 samples) by ELISA. For data analysis the PPCD patients were divided based on either the molecular genetic cause of their disease as PPCD1 (37 samples), PPCD3 (1 sample) and PPCDx (not linked to a known PPCD loci, 4 samples) or on the presence (17 samples) or absence (25 samples) of secondary glaucoma or on whether they had undergone penetrating keratoplasty (PK, 32 samples) or repeated PK (rePK, 7 samples). RESULTS: The level of active TGF-β2 in the AH of all PPCD patients (mean ± SD; 386.98 ± 114.88 pg/ml) in comparison to the control group (260.95 ± 112.43 pg/ml) was significantly higher (P = 0.0001). Compared to the control group, a significantly higher level of active TGF-β2 was found in the PPCD1 (P = 0.0005) and PPCDx (P = 0.0022) groups. Among patients the levels of active TGF-β2 were not significantly affected by gender, age, secondary glaucoma or by the progression of dystrophy when one or repeated PK were performed. CONCLUSION: The levels of active TGF-β2 in the AH of PPCD patients are significantly higher than control values, and thus the increased levels of TGF-β2 could be a consequence of the PPCD phenotype and can be considered as another feature characterizing this disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023139
003      
CZ-PrNML
005      
20170720122211.0
007      
ta
008      
170720s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0175509 $2 doi
035    __
$a (PubMed)28414732
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Stadnikova, Andrea $u Laboratory of the Biology and Pathology of the Eye, Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
245    10
$a Active transforming growth factor-β2 in the aqueous humor of posterior polymorphous corneal dystrophy patients / $c A. Stadnikova, L. Dudakova, P. Skalicka, Z. Valenta, M. Filipec, K. Jirsova,
520    9_
$a PURPOSE: Posterior polymorphous corneal dystrophy (PPCD) is characterized by abnormal proliferation of corneal endothelial cells. It was shown that TGF-β2 present in aqueous humor (AH) could help maintaining the corneal endothelium in a G1-phase-arrest state. We wanted to determine whether the levels of this protein are changed in AH of PPCD patients. METHODS: We determined the concentrations of active TGF-β2 in the AH of 29 PPCD patients (42 samples) and 40 cadaver controls (44 samples) by ELISA. For data analysis the PPCD patients were divided based on either the molecular genetic cause of their disease as PPCD1 (37 samples), PPCD3 (1 sample) and PPCDx (not linked to a known PPCD loci, 4 samples) or on the presence (17 samples) or absence (25 samples) of secondary glaucoma or on whether they had undergone penetrating keratoplasty (PK, 32 samples) or repeated PK (rePK, 7 samples). RESULTS: The level of active TGF-β2 in the AH of all PPCD patients (mean ± SD; 386.98 ± 114.88 pg/ml) in comparison to the control group (260.95 ± 112.43 pg/ml) was significantly higher (P = 0.0001). Compared to the control group, a significantly higher level of active TGF-β2 was found in the PPCD1 (P = 0.0005) and PPCDx (P = 0.0022) groups. Among patients the levels of active TGF-β2 were not significantly affected by gender, age, secondary glaucoma or by the progression of dystrophy when one or repeated PK were performed. CONCLUSION: The levels of active TGF-β2 in the AH of PPCD patients are significantly higher than control values, and thus the increased levels of TGF-β2 could be a consequence of the PPCD phenotype and can be considered as another feature characterizing this disease.
650    _2
$a komorová voda $x metabolismus $7 D001082
650    _2
$a rohovka $x metabolismus $7 D003315
650    _2
$a dědičné dystrofie rohovky $x metabolismus $7 D003317
650    _2
$a rohovkový endotel $x metabolismus $7 D004728
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glaukom $x metabolismus $7 D005901
650    _2
$a lidé $7 D006801
650    _2
$a keratoplastika perforující $x metody $7 D015948
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a transformující růstový faktor beta2 $x metabolismus $7 D053781
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dudakova, Lubica $u Laboratory of the Biology and Pathology of the Eye, Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
700    1_
$a Skalicka, Pavlina $u Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
700    1_
$a Valenta, Zdenek $u Department of Medical Informatics & Biostatistics, Institute of Computer Science, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Filipec, Martin $u European Eye Clinic Lexum, Prague, Czech Republic.
700    1_
$a Jirsova, Katerina $u Laboratory of the Biology and Pathology of the Eye, Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 12, č. 4 (2017), s. e0175509
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28414732 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720122704 $b ABA008
999    __
$a ok $b bmc $g 1238820 $s 984052
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 12 $c 4 $d e0175509 $e 20170417 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace